FDA Inspection 1197535 — Central Pennsylvania Blood Bank

Central Pennsylvania Blood Bank — FEI 1000161167

The FDA completed an inspection of Central Pennsylvania Blood Bank on February 2, 2023 in Ephrata, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
February 2, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Ephrata, PA (United States)